Evidence map›Paper›PMID 42472105›Full record

ReviewiScience2026

KAT8-mediated epigenetic modifications: Physiological functions, heterogeneity in disease, and advances in targeted development.

Zengjin Wang, Guanghui Ren, Peng Gao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zengjin WangMedical Research Central, Shandong Provincial Key Medical and Health Laboratory of Translational Medicine in Microvascular Aging, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan 250014, Shandong, China.
Guanghui RenDepartment of Pharmacy, The Second Qilu Hospital of Shandong University, Shandong University, 247 Beiyuan Street, Jinan 250033, Shandong, People's Republic of China.
Peng GaoMedical Research Central, Shandong Provincial Key Medical and Health Laboratory of Translational Medicine in Microvascular Aging, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan 250014, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

KAT8 (MOF/MYST1) is a core histone acetyltransferase of the MYST family. Beyond its canonical H4K16ac activity, KAT8 catalyzes diverse acylations and regulates stem cell biology, DNA repair, metabolism, and immunity. This review systematically integrates KAT8's regulatory networks across physiology and disease. We decipher the molecular basis of its context-dependent "double-edged sword" role in cancer, acting predominantly as an oncoprotein yet exhibiting tumor-suppressive functions under specific conditions. We evaluate current KAT8 inhibitor development, from early non-selective compounds to selective leads, and highlight persistent translational hurdles including insufficient specificity and limited

Indexed as

epigenetic regulationH4K16achistone acetyltransferaseKAT8KAT8 inhibitorsMOF/MYST1non-histone acetylationtumorigenic mechanisms

Identifiers

PMID42472105
PMCPMC13380446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.